1. Viral Hepatitis in Liver Transplantation
Gonzalo Crespo, Zoe Mariño, Miquel Navasa, Xavier Forns 
Gastroenterology 
Volume 142, Issue 6, Pages e1 (May 2012)
DOI: /j.gastro
Copyright © 2012 AGA Institute Terms and Conditions

2. Figure 1
Model of pathogenesis of accelerated fibrogenesis in patients with recurrent hepatitis C after LT. Recurrent hepatitis C is characterized by hepatocellular damage, infiltration of the liver with inflammatory cells, and tissue remodeling that ultimately results in progressive fibrosis and cirrhosis. Infiltrating inflammatory cells at the sites of liver injury secrete chemokines that stimulate hepatic stellate cells, which proliferate and produce extracellular matrix proteins. Indeed, stellate cells are key players in recurrent hepatitis C and these cells can be activated by a number of stimuli in the liver transplant setting: production of ROS (I/R injury, old donor), secretion of cytokines by immune cells (acute rejection, CMV infection), hyperglycemia, and chronic cholestasis (biliary complications). The combination of a variety of factors explains the accelerated progression of fibrosis in HCV-infected liver transplant recipients.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

3. Figure 2
Proposed algorithm for follow-up and management of hepatitis C recurrence following LT. DM, diabetes mellitus.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

4. Figure 3
Mechanisms and potential consequences of interactions between protease inhibitors and immunosuppressant drugs. Because both protease inhibitors (PI) and calcineurin inhibitors are metabolized by the CYP3A4 system, initiation of boceprevir or telaprevir therapy will increase CsA or TAC levels with the potential occurrence of severe adverse events: renal failure, hypertension, diabetes, or neurologic damage. On the contrary, interruption of boceprevir or telaprevir after treatment completion (or due to adverse effects) will precipitate a rapid decrease in CsA or TAC levels, which might lead to rejection episodes. TAC, tacrolimus; BOC, boceprevir; TVP, telaprevir.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

5. Gastroenterology 2012 142, 1373-1383. e1DOI: (10. 1053/j. gastro. 2012
Copyright © 2012 AGA Institute Terms and Conditions

6. Gastroenterology 2012 142, 1373-1383. e1DOI: (10. 1053/j. gastro. 2012
Copyright © 2012 AGA Institute Terms and Conditions

7. Gastroenterology 2012 142, 1373-1383. e1DOI: (10. 1053/j. gastro. 2012
Copyright © 2012 AGA Institute Terms and Conditions

8. Gastroenterology 2012 142, 1373-1383. e1DOI: (10. 1053/j. gastro. 2012
Copyright © 2012 AGA Institute Terms and Conditions